Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of leukapheresis products market are the result of an ongoing struggle to adapt to a fast-moving ecosystem motivated by the rising prevalence of blood diseases, the increased demand of more advanced therapeutic approaches, and the fact that continuous technological innovations do still occur in the field of medical devices. A procedure known as leukapheresis—which implies the separation of white blood cells from blood—has recently been appearing as an important module in the treatment of diverse hematological disorders including leukemia and lymphoma amongst others. The markets are noticing a sharp rise in demand for these technologies because there is a trend of worldwide increase in these diseases.
The market is highly stimulated by the growing incidence of blood-related disorders which include but not limited to anemia, leukemia and hemophilia. Undoubtedly, leukemia is an essential medical issue, hence, it might seem necessary that, more advanced treatment methods for its cure are developed. Recent therapy advancements such as leukapheresis have shown enormous promise in providing an effective way of separating and isolating white blood cells. Also The rising incidence of other blood disorders (particularly lymphoma and myeloma) gives a similar impact on the growing market volume.
One of the driving factors of the leukapheresis products market is the significant cultural need of development of ever more advanced therapies. With healthcare providers and patients in need of more precise and efficacious treatment procedures, apheresis leukocyte removal is rising as the main brig of cellular therapy preparation. The market has undergone a transformation towards personalized medicine. Instead, therapies become individualized, hinged on a person's unique genetic configuration. By removing patients’ T-cells (of the larger white blood cell group), targeted treatments, such as CAR-T therapy and stem-cell transplantation, can be created, thus, leekapheresis enables the use of the so-called precision medicine, which is an emerging trend in medicine.
The next essential element that affects the market is the technological advancement that has been implemented in medical equipment with device updates every other year. This trend underlines an effort by manufacturers in search of new leukapheresis products that exhibit efficient work, fast safe operations and better patient results. Developments using enclosed units for apheresis procedures with lowest possibility to spread infections are also creating additional market potential. Furthermore, it includes automation and complex computer software solutions which will simplify the procedure of manual leukophoresis and make it more accessible and effective for the health care professionals.
Spatially, leukapheresis products market showed various changes in the growth rates on the geographic front. The developed regions, which are followed by well-planned healthcare infrastructure and healthcare expenditure, are at the forefront of growth in this sector North America and Europe dominate on the grounds of the size of the market which they have, and this is in turn due to the combination of factors such as presence of blood disorders, the existence of detailed regulatory environment, and a higher rate of adoption of advanced medical technologies.
Leukapheresis Products Market Highlights:
Global Leukapheresis Products Market Overview
Leukapheresis products market is expected to reach USD 27.1 million at a CAGR 7.8% during the forecast period 2023-2032. Leukapheresis is a blood therapy that removes aberrant white blood cells (WBCs).
Leukemia can be treated using leukapheresis, or it can be utilized as the initial stage in CAR T-cell therapy. The rising number of blood donors, the rising prevalence of leukemia, and the demand for leukapheresis products in clinical trials are all expected to drive the market forward. The high cost of therapeutic leukapheresis, a scarcity of qualified experts, and strict donor recruitment requirements, on the other hand, may limit market expansion over the projection period. Despite its therapeutic potential, leukapheresis is currently a rare treatment option, especially for hyperleukocytosis leukemia.
January 2023: Sanguine Biosciences, a pioneer in the connection of patients with biopharmaceutical companies to expedite precision medicine R&D and Cell & Gene Therapy, today announced a new investment from BroadOak Capital Partners, LLC, a prominent direct investment and advisory firm that specializes in life science research tools, pharmaceutical services, and diagnostics. Sanguine's laboratory operations, leukapheresis offerings, and patient donor network are all enhanced by the partnership with BroadOak.
Sanguine introduced a new apheresis product family in October 2022, which offers researchers a substantial quantity of immune and hematopoietic stem cells from single donors with confirmed disease. The offering addresses a significant unmet need in the field of life science research and development, with a particular emphasis on the high-growth and high-impact cell and gene therapy sector. Biopharmaceutical researchers employ human biospecimens for biomarker development, which can result in innovative clinical applications as a result of the translation of bench discoveries into bedside treatments for patients.
However, the procurement and processing of pertinent patient samples for research purposes are complicated by the complexity of biologic- and cell-based therapies. Through partnerships with patient advocacy groups and a comprehensive recruitment apparatus, Sanguine Biosciences simplifies this process and provides researchers with access to a diverse, nationwide network of over 60,000 patient donors.
February 2021: Lonza has expanded its renowned human primary cell offerings with the introduction of high-quality cryopreserved Leukopaks that are entirely customizable. Leukopaks that are frozen will facilitate the long-distance shipment of leukapheresis products without the potential for diminished cell viability that is a concern with fresh Leukopaks. The cryopreserved Leukopaks are designed for long-term storage in research laboratories, and they also provide immediate access to viable cells, thereby enhancing workflow flexibility and convenience. The cryopreserved Leukopaks are available in a variety of sizes, and a distinctive costing structure enables customers to only pay for the customization that is required.
Additionally, customers have access to a variety of donor characteristics and testing options. A Leukopak is a product that is enriched through leukapheresis and contains high concentrations of peripheral blood mononuclear cells, including T cells, B cells, and monocytes. Before progressing to full clinical manufacturing, these cells are a critical raw material in immunotherapy research and for optimizing the development of the cell therapy process. Nevertheless, it can be challenging to obtain fresh Leukopaks and they must be used promptly to prevent cell degradation.
Therapeutic leukapheresis in the treatment of pediatric patients, on the other hand, is becoming a hot topic among industry participants. This is primarily due to the negative effects and hazards of traditional treatments for children, such as chemotherapy. Leukapheresis can be used to treat or remove excess WBCs in children with lymphoma, as well as to collect stem cells from children for other cancer patients. The possibilities and benefits of leukapheresis in this application make it a market focus, especially as only a few hospitals in both developed and emerging economies presently provide leukapheresis treatment for children.
Leukapheresis Products Market Segment Insights
The leukapheresis products market has been segmented into type, application, and end user.
Leukapheresis Products Type Insights
On the basis of type, the market has been segmented into leukapheresis devices and leukapheresis disposables. The leukapheresis devices segment has been segmented into apheresis devices, leukapheresis column & cell separators, and leukoreduction filters.
Leukapheresis Products Application Insights
The market, on the basis of application, has been segmented into research applications and therapeutic applications.
Leukapheresis Products End User Insights
On the basis of end user, the market has been segmented into blood component providers and blood centers, hospitals and transfusion centers, and others.
Leukapheresis Products Regional Insights
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukapheresis products market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European leukapheresis products market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The leukapheresis products market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukapheresis products market in the Middle East & Africa has been segmented into the Middle East and Africa.
Leukapheresis Products Market Top Key Players
some of the key players in the leukapheresis products market are
- Haemonetics
- Terumo BCT
- Asahi Kasei Medical
- STEMCELL Technologies
- Macopharma
- HemaCare Corporation
- Caltag Medsystem
- ALLCells LLC
- ZENBIO
- Fresenius Kabi
- PPA Research Group
- StemExpress
Regional Market Summary
Geographically, the Americas is anticipated to dominate the leukapheresis products market owing to the growing number of blood donations, rising incidence and prevalence of leukaemia and growing demand for leukopaks in clinical research. According to the America’s Blood Centers, more than 15 million pints of blood are transfused in the US each year.
Europe is expected to hold the second largest position in the leukapheresis products market. The market growth in this region is attributed to the increasing prevalence of leukemia and well-developed healthcare sector in the region. According to the Cancer Research UK, about 9,900 new cases of leukaemia were reported in UK in 2015.
The leukapheresis products market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the increasing presence of major multinational pharma and biotech companies, and improvement in healthcare access.
The Middle East & Africa has the lowest share of the leukapheresis products market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
Recent Development
Cryoport Inc. and Cell Matters SA formed a strategic agreement in February 2022 to provide end-to-end cryopreservation services for leukapheresis-derived therapies in the life sciences industry, enabling both autologous and allogeneic cell therapies. Terumo Blood and Cell Technologies revealed in July 2021 that physicians would be able to perform extracorporeal photopheresis immunotherapy (ECP) operations at the patient's bedside. Spectra Optia's functionality has been enhanced by the firm. These devices can now be used to perform the UVA PIT System ECP as a functionally closed, online, multistep system using mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols.
Leukapheresis Products Market Segmentation
Leukapheresis Products Type Outlook
- Leukapheresis Devices
- Apheresis Devices
- Leukapheresis Columns & Cell Separators
- Leukoreduction Filters
- Leukapheresis Disposables
Leukapheresis Products Application Outlook
- Research Applications
- Therapeutic Applications
Leukapheresis Products End User Outlook
- Blood Component Providers and Blood Centers
- Hospitals and Transfusion Centers
- Others
Leukapheresis Products Regional Outlook
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Intended Audience
- Apheresis Device Manufacturers and Distributors
- Leukapheresis Product Manufacturers and Distributors
- Pharmaceutical and Biotechnological Companies
- Healthcare Service Providers (including Hospitals and Transfusion Centers)
- Cancer Treatment Centers
- Blood Component Providers & Blood Centers
- Contract Research Organizations
- Academic and Research Institutes
- Government Associations
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
